Navigation Links
Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization
Date:10/25/2007

Proprietary technology identifies small molecule JAK2 and Pim kinase

inhibitors

SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced data as part of a series of presentations at the 2007 AACR-NCI-EORTC International Conference that describe how its proprietary CLIMB technology was used in lead development and design of small molecule JAK2 and Pim kinase inhibitors (Posters C200 and C208).

Poster C200 (Abstract No. 907)

Effect of small molecule inhibitors of JAK2 kinase on modulating signaling cascades downstream of cytokine receptors

Janus kinases (JAKs) are critical to a number of intracellular signaling pathways. Dysregulation of JAK2 signaling has been implicated in myoproliferative disorders, leukemia, lymphoma and various solid tumors. Utilizing CLIMB, SuperGen's proprietary technology, scientists used a JAK2 crystal structure to build several models that were made into a substrate for screening a large, virtual small molecule library. This process generated a subset of leads that were screened using in silico algorithms to identify "druggable" candidates to pursue.

Poster C208 (Abstract No. 985)

A small molecule inhibitor of Pim-1 kinase with activity in both hematological and solid tumor malignancies

Pim-1 kinase is involved in signaling pathways as a potent inhibitor of programmed cell death (apoptosis). Pim-1 is over expressed in many cancer types, including AML, CML, bladder and oral cancers. Scientists used SuperGen's CLIMB technology to build a model that allowed for the prediction of small molecule inhibitors. Leads were screened to identify those with inhibitory activity with low nanomolar IC50 concentrations. Data support further development of the lead compounds in liquid and solid tumors.

Copies of the poster presentations will be available in the pipeline section of SuperGen's Web site http://www.supergen.com.

"With our CLIMB technology we are able to decrease cycle times while identifying the most druggable candidates," said Dr. James S. Manuso, President and Chief Executive Officer. "This allows us to move at a rapid pace to select candidates that can be advanced into clinical trials."

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications & Manager, Investor Relations

Business Development Tel: (925) 560-2845

Tel: (925) 560-0100 E-mail: mary.vegh@supergen.com

E-mail: tenns@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
5. President Bush Ignores Americas Plea for Support of Stem Cell Research
6. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
7. Diabetes drug supported by Mexican Diabetes Federation
8. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
11. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb.8, 2016 Aesthetic Devices - ... Medical Devices sector report, "Aesthetic Devices - Medical Devices ... currently in pipeline stage. This report ... and primary research by GlobalData,s team of industry experts. ... removed or altered based on the availability and relevance ...
(Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016  Neurocrine ... the Company will report its fourth quarter and year-end ...  February 11, 2016.  Neurocrine will then host a live ... and provide a Company update Thursday afternoon, February 11, ... Time). http://www.neurocrine.com . --> http://www.neurocrine.com ...
(Date:2/8/2016)... N.J. , Feb. 8, 2016   GS1 ... healthcare professionals to guide them through GS1 Standards implementation ... Drug Administration (FDA) Unique Device Identification (UDI) rule. ... GS1 US; Beth Gibson , senior director industry ... , industry development director, GS1 US --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now ... country. The AutismOne 2016 Conference, which is being held May 25-29 at the Loews ... elsewhere about helpful interventions and causes of chronic illness in children. , Very recent ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... β€œTasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
Breaking Medicine News(10 mins):